<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864240</url>
  </required_header>
  <id_info>
    <org_study_id>10504909</org_study_id>
    <nct_id>NCT00864240</nct_id>
  </id_info>
  <brief_title>The Dose-response &quot;Pilot&quot; Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects</brief_title>
  <official_title>Dose Response of Clobex 0.05% Lotion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the dose-response relationship for Clobex TM (clobetasol propionate) Lotion,
      0.05%. This information will be used to estimate the ED50, D1, D2 parameters for use in a
      full bioequivalence study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: Randomized, open label, one period, dose response,
      vasoconstrictor assay study.

      Official Title: Dose Response of Clobex 0.05% Lotion

      Further study details as provided by Actavis Elizabeth LLC:

      Primary Outcome Measures:

      Â· Vasoconstrictor Response
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vasoconstriction response</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clobex TM 0.05% Lotion, single exposure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobex TM (Clobetasol) 0.05% Lotion, single exposure</intervention_name>
    <description>Subjects received Galderma Laboratories, L.P. formulated products</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Clobetasol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-tobacco-using female subjects, 18 to 50 years of age, inclusive.

          -  A demonstrated blanching response to Clobex TM (clobetasol propionate) Lotion, 0.05 %.

          -  A body mass index (BMI) 30 kg/m2 or less as calculated according to Novum Standard
             Operating Procedures.

          -  Good health as determined by lack of clinically significant abnormalities in medical
             history and clinical assessment, as judged by the Investigator.

          -  Signed and dated informed consent form which meets all criteria of current FDA
             regulations.

        Exclusion Criteria:

          -  History of allergy to any systemic or topical corticosteroid (including clobetasol) or
             to any cream, lotion, ointment, gel, cotton, soap, cosmetic, rubber, or tape, which in
             the opinion of the Investigator would compromise the safety of the subject or the
             study.

          -  Presence of any skin condition or coloration that would interfere with placement of
             test sites or the response or assessment of skin blanching.

          -  Significant history or current evidence of chronic infectious disease, system disorder
             (especially hypertension or circulatory disease), or organ dysfunction.

          -  Presence of a medical condition requiring regular treatment with prescription drugs.

          -  Drug or alcohol addiction requiring treatment (in-patient or out-patient) in the 12
             months prior to dosing.

          -  Use of any topical dermatological drug therapy (including topical corticosteroids) on
             the flexor surface of the ventral forearms in the 30 days prior to dosing.

          -  Use of any tobacco products in the 30 days prior to dosing.

          -  Receipt of any drug as part of a research study within 30 days prior to initial study
             dosing.

          -  Pregnant or lactating.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soran Hong,, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novum Pharmaceutical Research Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novum Pharmaceutical Research Services</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77042-4712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://chem.sis.nlm.nih.gov/chemidplus/ProxyServlet?objectHandle=DBMaint&amp;actionHandle=default&amp;nextPage=jsp/chemidlite/ResultScreen.jsp&amp;TXTSUPERLISTID=025122412</url>
    <description>CLOBETASOL</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christine Winslow, Director of Clinical Development</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Vasoconstriction</keyword>
  <keyword>Clobetasol</keyword>
  <keyword>Healthy adult females</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

